Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data

Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data

Objective: We present data of patients with relapsed/ refractory T cell lymphomas treated with brentuximab vedotin (BV) in real-world practice. Material and Method: This study is an observational, multi-center, retrospective study. The data of patients (n=17) treated with BV...

Full description

Bibliographic Details
Main Authors: Tahir Darcın, Istemi Serın, Mehmet Can Ugur, Omer Ekinci, İpek Yönal Hindilerden, Seval Akpınar, Tuba Hacıbekiroglu, Sinan Demircioğlu, Emine Gulturk, Murat Albayrak, İsmet Aydoğdu, Mehmet Sinan Dal, Mehmet Hilmi Doğu, Sinem Namdaroğlu, Ali Dogan, Meliha Nalçacı, Burhan Turgut, Semih Başcı, Fevzi Altuntaş
Format: Article
Language:English
Published: Hitit University 2024-06-01
Series:Hitit Medical Journal
Online Access:https://dergipark.org.tr/tr/doi/10.52827/hititmedj.1320606

Internet

https://dergipark.org.tr/tr/doi/10.52827/hititmedj.1320606

Similar Items